Latest Trials
| EudraCT Number: 2006-002576-18 | Sponsor Protocol Number: A4061027 | Start Date: 2006-11-24 | |||||||||||
| Sponsor Name: Pfizer Ltd. | |||||||||||||
| Full Title: A PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN PATIENTS METASTATIC OR UNRESECTABLE LOCALLY-ADVANCED THYROID CANCER REFRACTORY TO, OR NOT SUITABLE CANDIDATES FOR 131I TREATMENT | |||||||||||||
| Medical condition: Treatment of patients with 131I-refractory metastatic or unresectable locally-advanced papillary, follicular, or Hurthle-cell thyroid cancer who are also refractory to, or intolerant of, or have cl... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) IT (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||